Testing for COVID-19: a 2023 Update

Overview

Journal Aust Prescr

Date 2023 Dec 6

PMID 38053664

Authors

Ella M Meumann

Jennifer Mb Robson

Affiliations

Soon will be listed here.

Abstract

Nucleic acid amplification tests (NAATs), including polymerase chain reaction (PCR) assays, are more sensitive for the detection of SARS-CoV-2 than rapid antigen tests (RATS), and are the gold standard for diagnosis of acute COVID-19. However NAATs can remain positive for weeks following infection due to low-level shedding of non-viable viral fragments. RATs (in particular self-testing) are the mainstay of COVID-19 diagnosis due to their convenience, speed and high specificity. The sensitivity of RATs is highest within seven days of symptom onset. A negative RAT result may warrant a NAAT or repeat RAT for confirmation. The presence of spike antibodies is consistent with either vaccination or infection. Nucleocapsid antibodies suggest a previous infection. Serological tests measuring neutralising antibodies that infer immunity are not readily available.

Citing Articles

Communicating the Imperfect Diagnostic Accuracy of COVID-19 Rapid Antigen Self-Tests: An Online Randomized Experiment.

Li H, Kalra M, Zhu L, Ackermann D, Taba M, Bonner C Med Decis Making. 2024; 44(4):437-450.

PMID: 38651834 PMC: 11102651. DOI: 10.1177/0272989X241242131.

COVID-19 rapid antigen tests approved for self-testing in Australia: published diagnostic test accuracy studies and manufacturer-supplied information. A systematic review.

Bell K, Li Y, Medcalf E, Ackermann D Med J Aust. 2023; 219(11):551-558.

PMID: 37903650 PMC: 10952141. DOI: 10.5694/mja2.52151.

References

Lane C, Sherry N, Porter A, Duchene S, Horan K, Andersson P . Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study. Lancet Public Health. 2021; 6(8):e547-e556. PMC: 8270762. DOI: 10.1016/S2468-2667(21)00133-X. View

Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L . Cell-based Culture Informs Infectivity and Safe De-Isolation Assessments in Patients with Coronavirus Disease 2019. Clin Infect Dis. 2020; 73(9):e2952-e2959. PMC: 7665383. DOI: 10.1093/cid/ciaa1579. View

Wehrhahn M, Brown S, Newcombe J, Chong S, Evans J, Figtree M . An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population. J Clin Virol. 2021; 138:104797. PMC: 7968170. DOI: 10.1016/j.jcv.2021.104797. View

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

Hoang T, Goncalves da Silva A, Jennison A, Williamson D, Howden B, Seemann T . AusTrakka: Fast-tracking nationalized genomics surveillance in response to the COVID-19 pandemic. Nat Commun. 2022; 13(1):865. PMC: 8844306. DOI: 10.1038/s41467-022-28529-9. View

Brischetto A, Robson J . Testing for COVID-19. Aust Prescr. 2020; 43(6):204-208. PMC: 7738692. DOI: 10.18773/austprescr.2020.067. View

Carroll A, McNamara E . Comparison and correlation of commercial SARS-CoV-2 real-time-PCR assays, Ireland, June 2020. Euro Surveill. 2021; 26(6). PMC: 7879503. DOI: 10.2807/1560-7917.ES.2021.26.6.2002079. View

Akerman A, Milogiannakis V, Jean T, Esneau C, Silva M, Ison T . Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine. 2023; 90:104545. PMC: 10060887. DOI: 10.1016/j.ebiom.2023.104545. View

Dinnes J, Deeks J, Berhane S, Taylor M, Adriano A, Davenport C . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021; 3:CD013705. PMC: 8078597. DOI: 10.1002/14651858.CD013705.pub2. View

10.

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

11.

Rockett R, Basile K, Maddocks S, Fong W, Agius J, Johnson-Mackinnon J . Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. N Engl J Med. 2022; 386(15):1477-1479. PMC: 8929376. DOI: 10.1056/NEJMc2120219. View

12.

Jang S, Rhee J, Wi Y, Jung B . Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. Int J Infect Dis. 2020; 102:561-565. PMC: 7642732. DOI: 10.1016/j.ijid.2020.10.099. View

13.

Covid-Epidemiology And Surveillance Team . COVID-19 Australia: Epidemiology Report 79: Reporting period ending 24 September 2023. Commun Dis Intell (2018). 2023; 47. DOI: 10.33321/cdi.2023.47.72. View

14.

Crozier A, Rajan S, Buchan I, Mckee M . Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021; 372:n208. DOI: 10.1136/bmj.n208. View

15.

Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J . Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020; 25(32). PMC: 7427302. DOI: 10.2807/1560-7917.ES.2020.25.32.2001483. View

16.

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View